Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors

Stem Cells

Volumn 25, Issue 12, 2007, Pages 3194-3203

  Pearl Yafe, Michal ^a   Stein, Jerry ^a   Yolcu, Esma S ^b   Farkas, Daniel L ^c   Shirwan, Haval ^b   Yaniv, Isaac ^a   Askenasy, Nadir ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b University of Louisville School of Medicine   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Bone marrow transplantation; Differentiation; Fas

Indexed keywords

CASPASE 3; FAS ANTIGEN; FAS LIGAND;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL SURVIVAL; CELL TRANSPLANTATION; CLONOGENESIS; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; ISOMERIZATION; MICROENVIRONMENT; MOLECULAR INTERACTION; MOUSE; NONHUMAN; RADIATION PROTECTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CASPASE 3; CASPASE 8; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; FAS LIGAND PROTEIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED MRL LPR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC; TROPISM; UP-REGULATION;

MURINAE;

EID: 37349085887     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2007-0402     Document Type: Article

References (80)

1. Vinci G, Chouaib S, Autran B et al. Evidence that residual host cells surviving the conditioning regimen to allogeneic bone marrow transplantation inhibit donor hematopoiesis in vitro: The role of TNF-alpha. Transplantation 1991;52:406-411.
2. Moore MA. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 1991;78:1-19.
3. Metcalf D. Hematopoietic regulators: Redundancy or subtlety? Blood 1993;82:3515-3523.
4. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 1993;82:15-21.
5. Fairbairn LJ, Cowling GJ, Reipert BM et al. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell 1993;74:823-832.
6. Backx B, Broeders L, Bot FJ et al. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. Leukemia 1991;5:66-70.
7. Rusten LS, Jacobsen FW, Lesslauer W et al. Bifunctional effects of tumor necrosis factor alpha (TNF alpha) on the growth of mature and primitive human hematopoietic progenitor cells: Involvement of p55 and p75 TNF receptors. Blood 1994;83:3152-3159.
8. Jacobsen FW, Veiby OP, Stokke T et al. TNF-alpha bidirectionally modulates the viability of primitive murine hematopoietic progenitor cells in vitro. J Immunol 1996;157:1193-1199.
9. Caux C, Saeland S, Favre C et al. Tumor necrosis factor-alpha strongly potentiates interleukin-3 and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34+ hematopoietic progenitor cells. Blood 1990;75:2292-2298.
10. Jacobsen SE, Ruscetti FW, Dubois CM et al. Tumor necrosis factor alpha directly and indirectly regulates hematopoietic progenitor cell proliferation: Role of colony-stimulating factor receptor modulation. J Exp Med 1992;175:1759-1772.
11. Maciejewski J, Selleri C, Anderson S et al. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-3190.
12. Selleri C, Sato T, Anderson S et al. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995;165:538-546.
13. Nagafuji K, Takenaka K, Shibuya T et al. Fas antigen (CD95) and hematopoietic progenitor cells. Leuk Lymphoma 1996;24:43-56.
14. Takenaka K, Nagafuji K, Harada M et al. In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood 1996;88:2871-2877.
15. Sato T, Selleri C, Anderson S et al. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 1997;97:356-365.
16. Lepri E, Delfino DV, Migliorati G et al. Functional expression of Fas on mouse bone marrow stromal cells: Upregulation by tumor necrosis factor α and interferon γExp Hematol 1998;26:1202-1208.
17. Stahnke K, Hecker S, Kohne E et al. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol 1998;26:844-850.
18. Yang L, Dybedal I, Bryder D et al. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J Immunol 2005;174:752-757.
19. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003;3:745-756.
20. Zhang Y, Harada A, Bluethmann H et al. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: Increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood 1995;86:2930-2937.
21. Saheki K, Fujimori Y, Takemoto Y et al. Increased expression of Fas (APO-1, CD95) on CD34+ haematopoietic progenitor cells after allogeneic bone marrow transplantation Br J Haematol 2000;109:447-452.
22. Dybedal I, Bryder D, Fossum A et al. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 2001;98:1782-1791.
23. Aguila HL, Weissman IL. Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells. Blood 1996;87:1225-1231.
24. Traver D, Akashi K, Weissman IL et al. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998;9:47-57.
25. Pearl-Yafe M, Yolcu ES, Stein J et al. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 2007;35:1601-1612.
26. Barcena A, Park SW, Banapour B et al. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood 1996;88:2013-2025.
27. Domen J, Cheshier SH, Weissman IL. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med 2000;191:253-264.
28. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: Implication of surviving expression in normal hematopoiesis. Blood 2001;98:2091-2100.
29. Kim H, Whartenby KA, Georgantas RW et al. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. STEM CELLS 2002;20:174-182.
30. De Maria R, Testa U, Luchetti L et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93:796-803.
31. Alenzi FQ, Marley SB, Lewis JL et al. Regulation of hemopoietic progenitor cell number by the Fas/FasL apoptotic mechanism. Exp Hematol 2002;30:1428-1435.
32. Brazil JJ, Gupta P. Constitutive expression of the Fas receptor and its ligand in adult human bone marrow: A regulatory feedback loop for the homeostatic control of hematopoiesis. Blood Cells Mol Dis 2002;29:94-103.
33. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66:1403-1408.
34. Greil R, Anether G, Johrer K et al. Tuning the rheostat of the myelopoietic system via Fas and TRAIL. Crit Rev Immunol 2003;23:301-322.
35. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004;18:1176-1199.
36. Liu Y, Pop R, Sadegh C et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 2006;108:123-133.
37. Bryder D, Ramsfjell V, Dybedal I et al. Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation. J Exp Med 2001;194:941-952.
38. Dybedal I, Guan F, Borge OJ et al. Transforming growth factor-beta1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells. Blood 1997;90:3395-3403.
39. Baxter GT, Kuo RC, Jupp OJ et al. Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. J Biol Chem 1999;274:9539-9547.
40. Moreau G, Leite-De Moraes M, Ezine S et al. Natural killer cell-dependent apoptosis of peripheral murine hematopoietic progenitor cells in response to Fas cross-linking: Involvement of tumor necrosis factor-alpha. Blood 2001;97:3069-3074.
41. Pearl-Yafe M, Yolcu ES, Stein J et al. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and non-immunogenic interactions. STEM CELLS 2007;25:1448-1455.
42. Jones RJ, Celano P, Sharkis SJ et al. Two phases of engraftment established by serial bone marrow transplantation in mice. Blood 1989;73:397-401.
43. Jones RJ, Collector MI, Barber JP et al. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 1996;88:487-491.
44. Krause DS, Theise ND, Collector MI et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001;105:369-377.
45. Jang YY, Collector MI, Baylin SB et al. Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol 2004;6:532-539.
46. Yolcu ES, Askenasy N, Singh N et al. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002;17:795-808.
47. Singh NP, Yolcu ES, Askenasy N et al. ProtExTM: A novel technology to display exogenous proteins on the cell surface for immunomodulation. Ann NY Acad Sci 2005;1056:344-358.
48. Georgantas RW, Bohana-Kashtan O, Civin CI. Ex vivo soluble Fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. Transplantation 2006;82:471-478.
49. Biankin SA, Collector MI, Biankin AV et al. A histological survey of green fluorescent protein expression in 'green' mice: Implications for stem cell research. Pathology 2007;39:247-251.
50. Whartenby KA, Straley EE, Kim H et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002;100:3147-3154.
51. Stein J, Yaniv I, Askenasy N. Critical early events in hematopoietic cell seeding and engraftment. Folia Histochem Cytobiol 2005;43:191-195.
52. Dybedal I, Yang L, Bryder D et al. Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression. Blood 2003;102:118-126.
53. Peters SO, Kittler EL, Ramshaw HS et al. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 1996;87:30-37.
54. Von Drygalski A, Alespeiti G, Ren L et al. Murine bone marrow cells cultured ex vivo in the presence of multiple cytokine combinations lose radioprotective and long-term engraftment potential. Stem Cells Dev 2004;13:101-111.
55. Cerny J, Dooner M, McAuliffe C et al. Homing of purified murine lymphohematopoietic stem cells: A cytokine-induced defect. J Hematother Stem Cell Res 2002;11:913-922.
56. Lanzkron SM, Collector MI, Sharkis SJ. Hematopoietic stem cell tracking in vivo: A comparison of short-term and long-term repopulating cells. Blood 1999;93:1916-1921.
57. Traycoff CM, Cornetta K, Yoder MC et al. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential. Exp Hematol 1996;24:299-306.
58. Glimm H, Oh IL-H, Eaves CJ. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G2/M transit and do not reenter G0. Blood 2000;96:4185-4193.
59. Askenasy N, Yolcu ES, Yaniv I et al. Fas-ligand as a double-edged immunomodulator to induce transplantation tolerance. Blood 2005;105:1396-1404.
60. Josefsen D, Myklebust JH, Lynch DH et al. Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999;27:1451-1459.
61. Kennedy NJ, Kataoka T, Tschopp J et al. Caspase activation is required for T cell proliferation. J Exp Med 1999;190:1891-1896.
62. Budd RC. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest 2002;109:437-441.
63. Peter ME, Budd RC, Desbarats J et al. The CD95 receptor: Apoptosis revisited. Cell 2007;129:447-450.
64. Alderson MR, Armitage RJ, Maraskovsky E et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993;178:2231-2235.
65. Alam A, Cohen LY, Aouad S et al. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999;190:1879-1890.
66. Kennea NL, Stratou C, Naparus A et al. Functional intrinsic and extrinsic apoptotic pathways in human fetal mesenchymal stem cells. Cell Death Differ 2005;12:1439-1441.
67. Park H, Jung YK, Park OJ et al. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005;175:7193-7201.
68. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: A molecular switch for death or activation. Immunity 1999;11:783-793.
69. Yamada Y, Webber EM, Kirillova I et al. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: Requirement for type 1 but not type 2 receptor. Hepatology 1998;28:959-970.
70. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000;6:920-923.
71. Kimura M, Matsuzawa A. Autoimmunity in mice bearing lpr.cg: A novel mutant gene. Intl Rev Immunol 1994;11:193-210.
72. Pellegrini M, Bath S, Marsden VS et al. FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. Blood 2005;106:1581-1589.
73. Wallach D, Varfolomeev EE, Malinin NL et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-367.
74. Curtin JF, Cotter TG. Live and let die: Regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003;15:983-992.
75. Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003;14:53-66.
76. Park SM, Schickel R, Peter ME. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005;17:610-616.
77. Mohr A, Zwacka RM, Jarmy G et al. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 2005;24:2421-2429.
78. Kang TB, Ben-Moshe T, Varfolomeev EE et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol 2004;173:2976-2984.
79. Moore MAS. Cytokine and chemokine networks influencing stem cell proliferation, differentiation and marrow homing. J Cell Biochem 2002;38:29-38.
80. Bouscary D, De Vos J, Guesnu M et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11:839-845.